A Better Newspaper

OpenAI Goes Offensive on Cyber — and Reframes the Whole Security Market

OpenAI expanded its Daybreak cybersecurity program with an open-source patching initiative called Patch the Planet, an updated Codex Security plugin, a partner program, and the full release of GPT-5.5-Cyber, described as its most capable defensive AI model. SiliconANGLE notes the launch marks a shift in how OpenAI talks about AI and security.

Context: Contrast this with Anthropic withholding 'Claude Mythos' over dual-use offensive risk. OpenAI is making the opposite bet — ship defensive capability publicly and capture the enterprise security spend. The 'partner program' is the tell: OpenAI wants a channel and an ecosystem around security, not just a model. For the reader, the niche is integrators and managed-service plays that sit between GPT-5.5-Cyber and regulated buyers who can't deploy raw models.

Five Eyes: AI-Powered Attacks May Succeed 'Within Months'

Western governments and corporations warned, per the Financial Times, that AI-powered cyber threats may succeed within months and cautioned that their current lead in AI might not last long.

Context: Read alongside OpenAI's Daybreak push, this is the demand-side signal: a government-stamped warning compresses enterprise procurement timelines for AI-native security tooling. When Five Eyes puts a clock on it, regulated buyers — finance, healthcare, critical infrastructure — get budget cover to spend now. That's the window for anyone selling AI-defensive product or compliance wrappers.

China's AI Players Go Full-Stack as Chip Restrictions Loosen

On Bloomberg's Odd Lots, AI researcher Grace Shao describes how China's AI industry has evolved since DeepSeek's cheap frontier model briefly sank US tech stocks. Chinese companies, previously locked out of advanced chips, are now permitted to buy some Nvidia H200s, and large players like Baidu are pushing to become full-stack — building their own chips, models, and cloud infrastructure.

Context: This advances the US-China parity story in the wiki with a concrete shift: vertical integration. Full-stack Chinese players are less exposed to export controls and can undercut on the inference layer where China is already gaining share. For a strategist, the implication is that export controls are becoming a leakier moat, and the competitive battle is moving from training-chip access to deployment economics.

Physical AI Lands a Safety Framework and a Factory Platform Play

Nvidia announced Halos for Robotics, described as the industry's first full framework for building, testing, and managing AI robotics applications, aimed at robots that no longer operate within rigid pre-programmed rails. Separately, Google's Intrinsic unveiled at Automate 2026 an AI robotic prototype designed to help companies modularize factory floors with automated robotics.

Context: Two of the most powerful platform companies are racing to own the abstraction layer for physical AI — Nvidia on the safety/compliance stack, Google on the factory-floor orchestration. Whoever owns the safety framework owns the liability conversation, which is where the regulatory and insurance money will flow. Watch this as the robotics analog to the enterprise AI control plane: the governance layer is where the durable margin sits.

$380M Into Chipmaking Process Control — Where the Smart Capital Is Going

Dutch chip-manufacturing equipment maker Nearfield Instruments raised a $380 million Series D led by Fidelity, with participation from Walden Catalyst Ventures, Temasek, Innovation Industries, and M&G, to accelerate AI chipmaking.

Context: Capital is moving up the supply chain — not into models, but into the metrology and process-control gear that determines chip yield. With compute scarcity flagged as a 2026 structural bottleneck, the picks-and-shovels of fabrication are an underbuilt, capital-intensive niche with high barriers to entry. The Temasek/Fidelity composition signals sovereign and institutional money treating fab equipment as strategic infrastructure.

Apertus: An Open Foundation Model Pitched for Sovereign AI

Apertus, an open foundation model positioned explicitly for 'sovereign AI,' surfaced on Hacker News.

Context: Sovereign AI — governments and regulated industries wanting models they fully control and can audit — is becoming a real procurement category, dovetailing with EU AI Act compliance demands. Open, self-hostable foundation models are the supply side of that demand; worth tracking as a wedge against the closed-model incumbents in regulated markets.

The Moon's deep mantle may sit within reach of Artemis landing sites

By simulating the ancient impact that formed the South Pole-Aitken basin — the Moon's largest and oldest crater — scientists found that a low-angle strike from a large, iron-cored object blasted material from deep inside the Moon, including mantle rocks, toward the surface. That suggests deep lunar material could be accessible to future astronauts near planned Artemis landing sites.

Context: The commercial subtext: mantle and deep-crust material is where you'd expect concentrations of certain metals and where the Moon's geologic history (and resource map) is written. If the deepest, most valuable rock is sitting near the lunar south pole — already the focus of Artemis because of suspected water ice — it strengthens the case for the south pole as the first off-Earth mining frontier.

Two dietary fats pull insulin in opposite directions

Researchers found that palmitic acid — a saturated fat common in processed foods — may contribute to insulin resistance and type 2 diabetes by triggering inflammation, toxic fat buildup, and cellular stress. Oleic acid, the fat abundant in olive oil, appears to protect insulin function and may even counteract some of palmitic acid's harmful effects.

Context: Not new advice at the diet level, but the mechanistic detail matters commercially: it sharpens the scientific basis for 'fat-swap' reformulation in packaged foods and for nutraceutical and metabolic-health products positioned around oleic acid. The diabetes market is enormous and increasingly contested by GLP-1 drugs — but anything that clarifies the upstream metabolic biology feeds both food and pharma pipelines.

A butterfly that barely ages offers a new model for longevity research

Scientists found that Heliconius butterflies live several times longer than closely related species, with some showing little physical decline as they age. Their unusual pollen-feeding diet may contribute, but the research suggests deeper evolutionary adaptations are also helping them stay healthy longer.

Context: Comparative biology of unusually long-lived organisms (naked mole rats, certain whales, now these butterflies) is where much of the durable insight in the longevity field originates — the kind of foundational work that eventually seeds therapeutic targets, even if no product is anywhere close.

Two Mega-Deals in One Day: CRH and AbbVie Signal Where Strategic Capital Is Hunting

Irish building-materials group CRH agreed to buy Dallas-based construction group Arcosa for $8.5bn — its largest deal ever. Separately, AbbVie agreed to acquire Apogee for $10.9bn to add an inflammatory-disease drug, its biggest acquisition in more than five years, amid what the FT calls a surge of M&A in the pharma sector.

Context: Two things to read here. First, CRH — already North America's largest aggregates player — is doubling down on US infrastructure exposure, a bet on the multiyear federal/state buildout cycle and reshoring construction. Second, big pharma's M&A surge is a patent-cliff story: the majors face a wave of expirations late this decade and are buying late-stage pipelines rather than building them. The opportunity for you is in the second derivative — small/mid-cap biotechs with de-risked Phase II/III assets in inflammation, oncology and immunology are now repriced as acquisition targets, not standalone businesses.

Castlelake Goes Over Management's Head on EasyJet — A Private Credit Firm Flexing as Activist

EasyJet rebuffed three separate offers from investment firm Castlelake, prompting Castlelake to take its latest proposal — valuing the budget carrier at about £4.74bn ($6.3bn) — directly to shareholders. EasyJet's board rejected the bid as not in shareholders' best interest, accusing Castlelake of trying to buy the company "on the cheap."

Context: The interesting signal isn't the airline — it's the buyer. Castlelake is a credit/alternatives shop, not a strategic, going hostile on a public European name. When private credit funds start running activist-style public M&A campaigns, it tells you they see deep value the public market won't credit and have the dry powder to force the issue. Watch for this playbook to spread to other beaten-down European cyclicals trading below replacement value — the arbitrage is in front-running which names get a Castlelake-style approach next.

Godiva Japan Seeks LBO Loan Extension — Early Crack in Leveraged Buyouts

Godiva Japan is in talks with its banking syndicate to extend the repayment deadline on $464mn of leveraged buyout financing as the chocolate maker struggles in the major Asian market, according to people familiar with the matter.

Context: Small in isolation, but exactly the kind of canary worth tracking. Consumer LBOs done in a low-rate era are now meeting refinancing reality, and a struggling brand asking lenders for an extension rather than refinancing cleanly is a tell. For a litigation funder/distressed investor, the watchlist is consumer-discretionary buyouts with near-term maturity walls — that's where forced-seller situations and discounted secondary loan paper will surface first.

EM Earnings Beat Estimates for First Time in Four Years — The Trade the US-Obsessed Crowd Is Missing

For the first time in four years, companies in emerging markets are beating profit estimates, giving investors a fresh reason to believe the EM bull market is just getting started, Bloomberg reports.

Context: Earnings beats — not just multiple expansion — are the foundation of a durable rally, and EM has been a four-year underperformer that most US allocators are structurally underweight. With the Fed market pricing meaningful cuts this year (a weaker-dollar tailwind for EM assets), the contrarian setup is real: EM equities offer earnings momentum plus a currency kicker at a valuation discount. The risk is concentration — verify the beats aren't just a handful of mega-cap tech/commodity names before sizing in.

Polymarket: Fed rate cuts in 2026 (Yes) 80% ▼1 pts since yesterday

Pfizer Agrees in Principle to Resolve Depo-Provera Brain Tumor MDL

Pfizer has reached an agreement in principle to resolve thousands of lawsuits alleging it failed to warn that its Depo-Provera contraceptive injection is linked to meningioma brain tumors.

Context: This sets an early value anchor for a litigation that only gained momentum after the 2024 BMJ study tying high-dose progestogen exposure to meningioma risk. A settlement at the MDL stage — before bellwether verdicts established a damages range — suggests Pfizer saw enough exposure to pay rather than test causation in front of juries; watch the per-plaintiff allocation as a floor for any later filers.

Illinois Appellate Court Tosses $60M Mead Johnson NEC Verdict, Orders New Trial

An Illinois appellate court overturned a $60 million jury verdict awarded to a mother who claimed Mead Johnson's infant formula caused her premature son to develop necrotizing enterocolitis, a fatal intestinal disease. The court ordered a new trial.

Context: Another reversal in the cow's-milk-based formula NEC litigation, where defense-side appellate momentum has been mounting against the large early plaintiff verdicts. For funders, the reversal rate is now the key underwriting variable in this docket — high nominal verdicts mean little if they don't survive appeal.

Dexcom Warns of Stolen 'Scrap' G7 Sensors Resold Through Unauthorized Distributor

Dexcom is alerting users after discovering that two lots of Dexcom G7 continuous glucose monitoring sensors — originally set aside as scrap and intended for destruction — were stolen and resold through an unauthorized distributor, according to Top Class Actions.

Context: Worth monitoring but not yet a mass tort. Diabetic CGM users relying on defective scrap sensors face a clear personal-injury theory (missed hypo/hyperglycemic events), but the threshold question is harm at scale — how many compromised sensors reached patients and whether any adverse events occurred. Watch MAUDE for a clustering of G7 reports tied to these lot numbers; that would be the canary, not the alert itself.

US-Iran Peace Talks Show Early Progress in Switzerland, Moving Energy Markets

The first round of US-Iran negotiations in Switzerland ended with both sides agreeing on a roadmap toward a final deal to settle the four-month conflict, with Vice President Vance claiming a 'successful foundation' had been laid. Iran said there had been progress, sending oil lower on hopes for a recovery in Persian Gulf flows. European natural gas edged higher, however, after a rocky start to the talks and fresh threats from President Trump even as discussions proceeded.

Context: The path of this negotiation is the most important near-term driver for energy prices and broader risk sentiment. A durable deal that restores Gulf flows would ease oil and gas, support disinflation, and give the Fed more room to cut; a breakdown reintroduces a war premium. Prediction markets see regime collapse as effectively off the table and a US invasion as unlikely.

Polymarket: US invades Iran before 2027 14% · Iranian regime falls by June 30 0%

1957 Porsche 356A Carrera GS Sunroof Coupe — A Genuine Four-Cam

A 356A Carrera GS 'de Luxe' sunroof coupe, US-delivered new via Hoffman Motors of New York in August 1957, powered by the 1.5-liter 547/1 four-cam flat-four with roller-bearing crankshaft, dry-sump lubrication, and twin Solex carbs. The car has documented ownership across Colorado, Japan, the Netherlands, and Denmark, with a refurbishment, an interior re-trim, an engine overhaul, and a repaint in its original silver along the way.

Context: The Fuhrmann four-cam is the holy grail of pre-A/A 356 motors — hand-built, fiendishly complex, and produced in tiny numbers. Genuine four-cam Carreras trade in the high six to seven figures, and a sunroof GS de Luxe with this kind of paper trail is the kind of listing that sets, rather than follows, the market. If the four-cam is matching or correctly rebuilt, this is the only car on the list worth clearing your calendar for.

1965 Pontiac GTO Tri-Power 4-Speed — The Right Spec

A 1965 GTO hardtop with the Tri-Power 389 V8, four-speed manual, and Safe-T-Track diff, finished in burgundy over black. Sold with PHS Automotive Services documentation, owner's manual, service records, and a clean title.

Context: Tri-Power-and-four-speed is the configuration GTO buyers actually want — the combination that built the muscle-car legend before the carburetor was killed off for 1967. PHS documentation verifying the original drivetrain spec is exactly what separates a real one from a tribute, and it's the single biggest value lever on these cars.

1974 Ford Bronco Explorer — Built, Not Just Bought

An early Bronco with a documented overhaul: refit and aligned body panels, fresh orange paint, rebuilt 302 V8, three-speed automatic, rear axle, and twin-stick transfer case. Equipped with a lift kit on Bilstein shocks, manual locking hubs, front disc brakes, long-tube headers, and an Edelbrock carb and intake.

Context: Uncut, properly sorted first-gen Broncos remain one of the most liquid collector trucks in the market, and a fresh mechanical rebuild plus body work takes the guesswork out. Verify the body is uncut and the floors are solid — that's where these get expensive after the sale.

1986 Mercedes 560SL at No Reserve — The Sensible One

An R107 560SL in Smoke Silver over Palomino, sold new in Little Rock with documented Arkansas/Tennessee ownership, the 5.5-liter V8, both soft and removable hardtop, clean Carfax, and a clean title. Offered at no reserve.

Context: The 560SL is the most desirable US-market R107 — the biggest engine in the longest-running SL body. No reserve on a clean, well-documented two-tops car is where the bargains live; let the auction set the price and you may steal it under the comps.